sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
rosuvastatin/ezetimibe sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 10tk; 10mg+10mg 28tk
rosuvastatin/ezetimibe sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 20mg+10mg 30tk; 20mg+10mg 10tk; 20mg+10mg 90tk
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosupressandid - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosuppressants, valikuline immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
rosuvastatin/ ezetimibe teva õhukese polümeerikattega tablett
teva b.v. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 28tk; 10mg+10mg 10tk; 10mg+10mg 60tk; 10mg+10mg 30tk
rosuvastatin/ ezetimibe teva õhukese polümeerikattega tablett
teva b.v. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 20mg+10mg 60tk; 20mg+10mg 28tk; 20mg+10mg 30tk; 20mg+10mg 10tk
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriaas - immunosupressandid - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukeemia, müeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.